{"filings":[{"id":442566,"accession_number":"0001104659-26-061150","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2026-05-14T20:06:06+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elutia reports Q1 net loss $7.5M; NXT-41x on track for clearance in H1 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops $7.9M vs $1.9M loss in Q1 2025; net loss $7.5M vs $3.9M.","Cash & escrow $36.5M; NXT-41 510(k) clearance expected Q4 2026, NXT-41x clearance H1 2027.","Net sales $3.1M (+6% YoY); SimpliDerm $2.1M, Cardiovascular $1.0M.","Adjusted gross margin 66.5% vs 55.9% YoY; new automated mfg supports >80% gross margin target.","Exploring SimpliDerm divestiture; received inbound inquiries for Cardiovascular product line."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107556,"accession_number":"0001104659-26-026398","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elutia Q4 revenue $3.3M (+16% YoY); NXT-41 510(k) submitted; cash $36.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net sales from continuing ops $3.3M, up 16% YoY; adjusted gross margin 66.8%.","Full year net sales $12.3M; net loss from continuing ops $15.9M; net income $53.4M includes gain on BioEnvelope sale.","Submitted 510(k) for NXT-41 base biologic matrix to FDA; clearance expected H2 2026; full NXT-41x clearance in 1H27.","Closed $88M BioEnvelope sale to Boston Scientific; repaid $26.9M debt; cash $36.4M plus $8M escrow.","Initiated strategic review for SimpliDerm product line to focus on NXT-41x launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107555,"accession_number":"0001104659-26-025311","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Elutia adopts 2026 Inducement Award Plan, authorizing up to 2M shares for new hire grants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board adopted Inducement Plan on March 3, 2026; allows equity grants to new employees as hiring inducement without shareholder approval.","Maximum shares authorized: 2,000,000 shares of Class A common stock.","Awards include stock options (non-ISO), SARs, restricted stock, RSUs, cash-based awards, and dividend equivalents.","Plan administered by Compensation Committee; awards subject to Company's clawback policies.","Grants require press release and Nasdaq notice under Nasdaq Rule 5635(c)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107554,"accession_number":"0001104659-26-023189","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Elutia regains full compliance with Nasdaq minimum bid price and MVLS requirements","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on March 2, 2026, confirming compliance with minimum bid price rule (bid ≥ $1.00 for 10 consecutive days).","Received Nasdaq notice on February 5, 2026, confirming compliance with MVLS requirement (MVLS ≥ $35M for 11 consecutive days).","All Nasdaq continued listing requirements are now met; matters are closed; stock continues trading on Nasdaq Capital Market under symbol ELUT.","CFO Matt Ferguson cites investor confidence in drug-eluting biomatrix technology platform and market opportunity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107553,"accession_number":"0001104659-26-002742","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elutia reports preliminary Q4 2025 revenue $3.3M (+16% YoY); eliminates $26.9M debt","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 net sales ~$3.3M, up 16% YoY, excluding divested BioEnvelope business.","Repaid full $26.9M debt to SWK Holdings, significantly cutting interest expense.","Cash on hand $36.3M; $8M escrow from BioEnvelope divestiture expected in 2026.","Plans FDA filing for NXT-41 base matrix in H1 2026, clearance H2 2026; NXT-41x clearance H1 2027.","CEO cites $88M EluPro divestiture to Boston Scientific as transformational, funding NXT-41x."],"consensus_eps_estimate":null,"consensus_eps_actual":0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":12293000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107552,"accession_number":"0001104659-26-000076","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Elutia receives Nasdaq delisting notice for MVLS below $35M, also still out of compliance with bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice received Dec 23, 2025: MVLS below $35M for 30 consecutive business days.","Company has 180 days (until June 22, 2026) to regain MVLS compliance.","Previously disclosed bid price non-compliance; cure period ends May 6, 2026.","Stock continues trading on Nasdaq Capital Market (ELUT) pending compliance efforts.","Company may seek a reverse stock split if needed to cure bid price deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123916,"accession_number":"0001104659-25-109699","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Elutia receives Nasdaq deficiency notice for bid price below $1.00 per share","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Elutia on Nov 7, 2025 that its common stock closed below $1.00 for 30 consecutive business days.","Company has 180 days (until May 6, 2026) to regain compliance by closing at $1.00+ for 10 consecutive days.","If not cured, Elutia may request an additional 180-day period if it meets market value and other initial listing standards.","Stock continues trading on Nasdaq under 'ELUT' while the company monitors options, including a potential reverse stock split.","No immediate delisting; failure to cure could lead to delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123915,"accession_number":"0001104659-25-107741","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elutia Q3 revenue $3.3M, closes $88M BioEnvelope sale to Boston Scientific, pays off debt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net sales $3.3M (down from $3.7M YoY); loss from operations $5.2M vs $9.2M loss a year ago.","Closed sale of BioEnvelope business to Boston Scientific for $88M; used $27.8M to repay SWK loan facility in full.","Advancing NXT-41x for plastic/reconstructive surgery; FDA clearance of base matrix expected 2H26, drug-eluting version 1H27.","Cash balance $4.7M at Sep 30, 2025; received $80.3M net proceeds on Oct 1, 2025 after closing and escrow.","Settled 7 additional FiberCel cases, leaving only 6 unresolved; Guido J. Neels appointed to Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123914,"accession_number":"0001104659-25-099347","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Elutia appoints medtech veteran Guido Neels to board; Jordan and Zuga resign","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Guido J. Neels elected to board effective Oct 9, 2025; appointed to Audit Committee.","Neels granted option for 171,916 shares at $0.88, vesting over 3 years.","Maybelle Jordan and W. Matthew Zuga resigned Oct 8, 2025; no disagreement cited.","Neels is Operating Partner at EW Healthcare Partners and former COO of Guidant.","Company notes recent EluPro divestiture as context for strategic transformation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123913,"accession_number":"0001104659-25-097561","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["1.01","2.01","7.01","8.01","9.01"],"status":"ready","headline":"Elutia closes $88M sale of BioEnvelope business to Boston Scientific; pivots to NXT-41x","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed sale of CIED/BioEnvelope business to Boston Scientific for $88M cash; $80.3M paid at closing, $8M escrowed for 12 months.","Used $27.8M of proceeds to fully repay and terminate SWK Credit Agreement (principal $24.5M plus fees).","Amended Ligand royalty agreement: paid $1.1M accrued royalties; Ligand consented to sale and released security interest in CIED assets.","Company will focus on NXT-41x drug-eluting biomatrix for breast reconstruction; expects launch first half 2027.","Pro forma cash balance ~$57M; Device Protection Business reported as discontinued operations in future filings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140585,"accession_number":"0001104659-25-088481","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Elutia sells CIED business to Boston Scientific for up to $88M; funds breast reconstruction pipeline","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Asset sale of EluPro/CanGaroo bioenvelope business to Boston Scientific (BSX) for $80M at closing plus $8M escrow.","Proceeds to eliminate outstanding debt, resolve Orthobiologics litigation, and fund NXT-41 advancement without dilution.","Transaction expected to close in Q4 2025, subject to customary closing conditions.","Elutia to focus resources on SimpliDerm franchise and drug-eluting pipeline in the $1.5B US breast reconstruction market.","BofA Securities served as financial advisor to Elutia on the sale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140584,"accession_number":"0001104659-25-080916","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Elutia amends SWK credit facility, capitalizes interest and fees into principal","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Fifth Amendment to $25M senior secured term loan capitalizes accrued interest due Aug 2025, $50k amendment fee (June 30, 2025), and $10k amendment fee.","No new principal borrowed; amendment modifies repayment terms of existing SWK Facility.","Amendment effective Aug 14, 2025; no event of default occurred and continuing.","Borrower represents all conditions precedent satisfied, including payment of $10k amendment fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140583,"accession_number":"0001104659-25-078596","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elutia Q2 BioEnvelope revenue $3.5M (+33% YoY), EluPro sales surge 49% sequentially","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["EluPro drug-eluting envelope revenue up 49% sequentially; now ~2/3 of BioEnvelope sales; average per-customer spend 130% higher vs legacy CanGaroo.","Total Q2 net sales $6.3M (flat YoY); SimpliDerm $2.0M (down from $2.6M); Cardiovascular $0.7M (down from $1.1M).","GAAP gross margin improved to 48.8% (vs 44.5%); adjusted gross margin 62.4% (vs 58.0%); net loss narrowed to $9.6M (vs $28.2M).","Litigation substantially resolved: settled 27 additional FiberCel cases for total 97 of 110; expect reduced litigation expenses.","Pipeline: progressing NXT-41 antibiotic biomatrix for breast reconstruction; FDA clearance targeted 2H26 (base) and 1H27 (drug-eluting); addresses $1.5B market."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":12293000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158291,"accession_number":"0001558370-25-008401","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Elutia annual meeting elects two Class II directors, ratifies PwC as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["29,585,703 shares (80.9% of outstanding) present at May 29, 2025 annual meeting.","Brigid A. Makes elected as Class II director: 19,152,084 FOR, 5,806,525 WITHHELD.","C. Randal Mills, Ph.D. elected as Class II director: 21,801,664 FOR, 3,156,945 WITHHELD.","Ratification of PricewaterhouseCoopers as auditor for FY2025: 29,581,065 FOR, 4,458 AGAINST, 180 abstained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158290,"accession_number":"0001104659-25-046155","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["1.01","2.02","3.02","9.01"],"status":"ready","headline":"Elutia Issues Shares to Ligand, Amends SWK Loan, and Reports 84% Sequential EluPro Growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Issued 1,105,528 shares to Ligand Pharmaceuticals to satisfy $2.2 million in royalty obligations.","Amended SWK credit facility allowing full PIK interest in May 2025 and potential $5.0 million additional term loan.","Reported Q1 2025 net sales of $6.0 million; BioEnvelope sales up 31% year-over-year to $3.1 million driven by 84% sequential EluPro growth.","Entered partnership with Boston Scientific expected to accelerate EluPro adoption starting Q2 2025.","Cash balance of $17.4 million as of March 31, 2025; raised $15.0 million in gross proceeds from direct offering."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":6030000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158289,"accession_number":"0001104659-25-045050","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["1.02","7.01","9.01"],"status":"ready","headline":"Elutia terminates LeMaitre distribution deal, moves to direct cardiovascular sales","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Termination of distribution agreement with LeMaitre Vascular for ProxiCor, VasCure, Tyke products in the U.S.","Appoints Dwayne Montgomery as Head of Cardiovascular; recruits 26 independent sales reps for new direct sales unit.","Expects ~80% gross margins and top-line growth; 2024 cardiovascular product sales were $2.9M (12% of revenue).","No early termination penalties incurred; transition to direct sales has commenced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176670,"accession_number":"0001104659-25-021371","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elutia Q4 2024: BioEnvelope sales +18% to $2.7M; EluPro pilot launch gains traction; net loss $9.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 BioEnvelope sales $2.7M (+18% YoY); overall net sales $5.5M (-7% YoY) due to SimpliDerm and cardiovascular declines.","EluPro accounted for over 30% of BioEnvelope sales in Q4; 67 approved accounts and ~100 actively ordering.","Q4 GAAP gross margin improved to 42.5% (from 36.2%); adjusted gross margin 58.1% (from 50.6%).","Full year 2024 net loss from continuing ops $54.1M vs $41.2M; adjusted EBITDA loss narrowed to $12.9M from $14.4M.","Year-end cash $13.2M; raised ~$15M gross proceeds in February 2025 registered direct offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176669,"accession_number":"0001104659-25-009187","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Elutia raises $15M in registered direct offering; sells 5.52M shares at $2.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $15.0M from sale of 5,520,000 shares at $2.50 and 480,000 prefunded warrants at $2.499.","Prefunded warrants have $0.001 exercise price, exercisable immediately, and expire when fully exercised.","Net proceeds to be used for working capital and general corporate purposes.","Directors and officers subject to 90-day lock-up; company also restricted from issuing equity for 90 days post-close."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176668,"accession_number":"0001104659-25-008297","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"Elutia prelim FY2024 net sales $24.4M, down 1% YoY; cardiovascular sales plunge 42%","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Preliminary 2024 net sales $24.4M vs $24.7M in 2023, a 1% decline.","Women's health sales grew 12% to $11.6M; device protection up 5% to $9.9M.","Cardiovascular sales fell 42% to $2.9M, dragging overall results.","Results are preliminary; final numbers subject to adjustment upon completion of year-end close.","No further financial details provided; full 10-K to follow."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193507,"accession_number":"0001104659-24-118906","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elutia Q3 net sales $5.9M (-3.3%); EluPro adoption accelerates with 100+ VAC submissions","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Overall Q3 net sales $5.9M, down 3.3% YoY; BioEnvelope sales down 12% to $2.3M as customers await EluPro.","SimpliDerm sales up 19% to $3.1M; adjusted gross margin improved to 61% from 60%.","Net income from cont. ops $1.3M driven by $12.7M non-cash warrant revaluation gain; adjusted EBITDA loss $2.9M.","EluPro: first patient implant, over 100 VAC submissions, 36 accounts ordering; full commercial launch set for Jan 2025.","Cash balance $25.7M as of Sep 30, 2024, includes $13.8M from warrant exercises in early Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":18907000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193506,"accession_number":"0001104659-24-105839","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Elutia amends credit agreement, deferring principal repayments by one year to Nov 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal repayment commencement deferred from Nov 15, 2024 to Nov 15, 2025.","Interest paid-in-kind election extended to Nov 15, 2025.","Exit fee increased by $50,000 to 6.50% plus $112,500.","SWK Facility remains a $25M senior secured term loan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209814,"accession_number":"0001104659-24-086740","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elutia Q2 net loss widens to $28.2M on warrant revaluation; EluPro launch underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $28.2M vs $10.6M YoY; includes $18.3M non-cash warrant revaluation charge.","Total net sales flat at $6.3M; CanGaroo +19% to $2.6M, SimpliDerm +7% to $2.6M.","FDA clearance for EluPro received; manufacturing commenced; commercial team expanding.","Cash $18.2M at quarter end; $13.8M additional from post-quarter warrant exercises.","Adjusted EBITDA loss improved to $2.9M from $3.4M in prior-year quarter."],"consensus_eps_estimate":-0.1734,"consensus_eps_actual":-1.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":12985000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228012,"accession_number":"0001104659-24-072818","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Elutia raises $13.26M in registered direct offering of 3.175M shares and prefunded warrants at $3.40/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$13.26M from sale of 3,175,000 shares and 725,000 prefunded warrants.","Offering price $3.40 per share; prefunded warrants $3.399 each, exercisable at $0.001.","Net proceeds to be used for working capital and general corporate purposes.","Lake Street Capital Markets acted as placement agent; 7.0% cash fee on gross proceeds.","Directors and officers subject to 90-day lock-up on company securities post-closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228011,"accession_number":"0001104659-24-072044","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Elutia receives FDA clearance for antibiotic-eluting bioenvelope EluPro for cardiac and neuromodulation devices","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared EluPro, first antibiotic-eluting bioenvelope, for pacemakers, defibrillators, neurostimulators, and neuromodulators.","Targets $600M US implantable electronic device protection market; no other biologic competitor currently.","Delivers rifampin and minocycline embedded in extracellular matrix to reduce infection, migration, and erosion complications.","Additional indications expand addressable market to neurostimulation/modulation, estimated at $8B worldwide.","Elutia plans national CIED launch in H2 2024; adjacent neuro markets prioritized for expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228010,"accession_number":"0001558370-24-009020","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Elutia stockholders elect Maybelle Jordan and W. Matthew Zuga as Class I Directors at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Turnout 12,975,682 shares (64.8% of outstanding Class A common stock) at June 6, 2024 annual meeting.","Maybelle Jordan received 10,789,009 votes FOR (160,550 withheld) to serve as Class I director until 2027.","W. Matthew Zuga received 10,670,337 votes FOR (279,222 withheld) to serve as Class I director until 2027.","Ratification of PwC as independent auditor for FY 2024: 12,966,730 FOR, 251 AGAINST, 8,701 ABSTAINED."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228009,"accession_number":"0001104659-24-059460","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elutia Q1 net sales $6.7M; SimpliDerm up 55%; CanGarooRM FDA decision expected by June 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["SimpliDerm net sales $3.6M (+55% YoY) driven by accelerated adoption in $1.6B breast reconstruction market.","CanGarooRM antibiotic-envelope 510(k) submission; positive FDA interactions; clearance anticipated Q2 2024.","Net loss $18.0M includes $9.6M non-cash warrant revaluation; adjusted EBITDA loss improved to $3.6M.","Cash balance $12.6M; preparing for CanGarooRM commercial launch in H2 2024.","Overall net sales $6.7M (+5% YoY); cardiovascular sales declined 56% due to LeMaitre distribution transition."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":6694000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228008,"accession_number":"0001558370-24-004550","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Elutia amends credit agreement, reducing minimum revenue covenant to $20M from $41M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Second Amendment with SWK Funding LLC lowers minimum Aggregate Revenue to $20M for trailing twelve months from Q1 2024 onward.","Previous covenant was $41M for Q2 2023 and each subsequent quarter; now reduced to $20M.","Amendment executed March 27, 2024; filed as Exhibit 10.1 on April 1, 2024.","No other material terms changed; CFO Matt Ferguson signed on behalf of Elutia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246772,"accession_number":"0001104659-24-031918","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elutia reports FY23 net loss $37.7M, cash $19.3M; CanGarooRM 510(k) decision expected H1 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year net sales $24.7M vs $23.8M; SimpliDerm up 38%, CanGaroo up 3.4%.","GAAP gross margin 45%; adjusted gross margin 58%; net loss $37.7M vs $32.9M.","Adjusted EBITDA loss improved to $14.6M from $22.9M.","Cash $19.3M as of Dec 31, 2023; proceeds $14.6M from orthobiologics divestiture.","FDA 510(k) decision for CanGarooRM expected in first half 2024; no additional data requested."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}